Company Profile

Coherus BioSciences, Inc. Stock Price, News & Catalysts

Ticker:
CHRS
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

0.39 USD (-5.56%)

Close

Last updated: November 19, 2026

234M USD

Market cap

Why the stock is moving

As of Nov 19, 2026, CHRS closed down 5.56% at $0.3871. No new same-company headline was identified in the current news window.

Company overview

Immuno-Oncology Portfolio

Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI.

Casdozokitug

Casdozokitug is an anti-IL-27 antibody being studied with LOQTORZI in first-line hepatocellular carcinoma. The program targets IL-27-mediated immune suppression and is being evaluated in a randomized Phase 2 trial.

Tagmokitug

Tagmokitug is a CCR8-directed antibody designed to selectively deplete regulatory T cells in tumors. Combination studies with toripalimab span head and neck, upper gastrointestinal, esophageal and colorectal cancers.

Oncology Portfolio Prioritization

Coherus is concentrating tagmokitug development on esophageal cancer while continuing the casdozokitug hepatocellular-carcinoma study and selected combination programs.

Future catalysts

  • FDA alignment on an expedited development path and study design for tagmokitug plus toripalimab in second-line esophageal cancer.
  • Initiation of a new tagmokitug-plus-toripalimab study in second-line esophageal cancer.
  • Initial data from the randomized Phase 2 casdozokitug combination study in first-line hepatocellular carcinoma in the first half of 2027.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Coherus BioSciences, Inc. (CHRS)?

Coherus BioSciences, Inc. (CHRS) most recently closed at 0.39 USD, a -5.56% move versus the previous session.

What is the market cap of Coherus BioSciences, Inc. (CHRS)?

Coherus BioSciences, Inc. currently has a market capitalization of 234M USD on BioPharmSignal.

What does Coherus BioSciences, Inc. do?

Immuno-Oncology Portfolio Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI. Casdozokitug Casdozokitug is an anti-IL-27 antibody being studied with LOQTORZI in...

On which exchange is CHRS stock listed?

Coherus BioSciences, Inc. (CHRS) is associated with NASDAQ, United States, Biopharma.

What is IL-27?

Casdozokitug Casdozokitug is an anti-IL-27 antibody being studied with LOQTORZI in first-line hepatocellular carcinoma.

Which conditions is Coherus BioSciences, Inc. targeting with IL-27?

Coherus BioSciences, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.

How does Coherus BioSciences, Inc. describe recent progress with IL-27?

FDA alignment on an expedited development path and study design for tagmokitug plus toripalimab in second-line esophageal cancer. Initiation of a new tagmokitug-plus-toripalimab study in second-line esophageal cancer. Initial data from the randomized Phase 2 casdozokitug combination study in first-line hepatocellular carcinoma in the first half of 2027.

What is toripalimab?

Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI.